Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease

Journal of Neurochemistry

Volumn 74, Issue 1, 2000, Pages 237-243

  Guan, Zhi Zhong ^a   Zhang, Xiao ^a   Ravid, Rivka ^a,b   Nordberg, Agneta ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NETHERLANDS BRAIN BANK   (Netherlands)

Author keywords

Alzheimer's disease; Neuronal nicotinic acetylcholine receptor; Postmortem brain; Western blot

Indexed keywords

ION CHANNEL; NICOTINIC RECEPTOR; RECEPTOR SUBUNIT;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RECEPTOR BINDING; TEMPORAL CORTEX;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANIMALS; BLOTTING, WESTERN; CADAVER; CELL LINE; FEMALE; FIBROBLASTS; HIPPOCAMPUS; HUMANS; MALE; MICE; NEUROBLASTOMA; PROTEIN ISOFORMS; RECEPTORS, NICOTINIC; REFERENCE VALUES; TEMPORAL LOBE;

HIPPOCAMPUS HIPPOCAMPUS;

EID: 0033983966     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2000.0740237.x     Document Type: Article

References (61)

1. Alonso A. C., Zaidi T., Grundke-Iqbal I., and Iqbal K. (1994) Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc. Natl. Acad. Sci. USA 91, 5562-5566.
2. 3H]nicotine binding sites in human brain. J. Neurochem. 50, 1243-1247.
3. Bjercke R. J. and Langone J. J. (1989) Anti-idiotypic antibody probes of neuronal nicotinic receptors. Biochem. Biophys. Res. Commun. 162, 1085-1092.
4. Braak H., Braak E., Bohl J., and Reintjes R. (1996) Age, neurofibrillary changes, A beta-amyloid and the onset of Alzheimer's disease. Neurosci. Lett. 210, 87-90.
5. Chavez-Noriega L. E., Crona J. H., Washburn M. S., Urrutia A., Elliott K. J., and Johnson E. C. (1997) Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h α2β2, h α2β4, h α3β2, h α3β4, h α4β2, h α4β4 and h α7 expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 280, 346-356.
6. Chen D. and Patrick J. W. (1997) The alpha-bungarotoxin-binding nicotinic acetylcholine receptor from rat brain contains only the α7 subunit. J. Biol. Chem. 272, 24024-24029.
7. Chini B., dementi F., Hukovic N., and Sher E. (1992) Neuronal-type α-bungarotoxin receptors and the α5-nicotinic receptor subunit gene are expressed in neuronal and nonneuronal human cell lines. Proc. Natl. Acad. Sci. USA 89, 1572-1576.
8. Davila-Garcia M. I., Houghtling R. A., Qasba S. S., and Kellar K. J. (1999) Nicotinic receptor binding sites in rat primary neuronal cells in culture: characterization and their regulation by chronic nicotine. Brain Res. Mol. Brain Res. 66, 14-23.
9. DeKosky S. T. and Scheff S. W. (1990) Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann. Neurol. 27, 457-464.
10. Edelberg H. K. and Wei J. Y. (1996) The biology of Alzheimer's disease. Mech. Ageing Dev. 91, 95-114.
11. Elliott K. J., Ellis S. B., Berckhan K. J., Urrutia A., Chavez-Noriega L. E., Johnson E. C., Velicelebi G., and Harpold M. M. (1996) Comparative structure of human neuronal α2-α7 and β2-β4 nicotinic acetylcholine receptor subunits and functional expression of the α2, α3, α4, α7, β2, and β4 subunits. J. Mol. Neurosci. 7, 217-228.
12. Farlow M. R. and Evans R. M. (1998) Pharmacologic treatment of cognition in Alzheimer's dementia. Neurology 51, S36-S44; Discussion S65-S67.
13. Farooqui A. A., Wells K., and Horrocks L. A. (1995) Breakdown of membrane phospholipids in Alzheimer disease. Involvement of excitatory amino acid receptors. Mol. Chem. Neuropathol 25, 155-173.
14. Felician O. and Sandson T. A. (1999) The neurobiology and pharmacotherapy of Alzheimer's disease. J. Neuropsychiatry Clin. Neurosci. 11, 19-31.
15. Flores C. M., Rogers S. W., Pabreza L. A., Wolfe B. B., and Kellar K. J. (1992) A subtype of nicotinic cholinergic receptor in rat brain is composed of α4 and β32 subunits and is up-regulated by chronic nicotine treatment. Mol. Pharmacol. 41, 31-37.
16. Galzi J. L. and Changeux J. P. (1995) Neuronal nicotinic receptors: molecular organization and regulations. Neuropharmacology 34, 563-582.
17. Gerzanich V., Peng X., Wang F., Wells G., Anand R., Fletcher S., and Lindstrom J. (1995) Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Mol. Pharmacol. 48, 774-782.
18. Gomez-Isla T., Hollister R., West H., Mui S., Growdon J. H., Petersen R. C., Parisi J. E., and Hyman B. T. (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 41, 17-24.
19. Gotti C., Fornasari D., and Clementi F. (1997a) Human neuronal nicotinic receptors. Prog. Neurobiol. 53, 199-237.
20. Gotti C., Moretti M., Maggi R., Longhi R., Hanke W., Klinke N., and Clementi F. (1997b) α7 and α8 nicotinic receptor subtypes immunopurified from chick retina have different immunological, pharmacological and functional properties. Eur. J. Neurosci. 9, 1201-1211.
21. Gray R., Rajan A. S., Radcliffe K. A., Yakehiro M., and Dani J. A. (1996) Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature 383, 713-716.
22. Guan Z. Z., Zhang X., Blennow K., and Nordberg A. (1999) Decreased protein level of nicotinic receptor α7 subunit in the frontal cortex from schizophrenic brain. Neuroreport 10, 1779-1782.
23. Hellström-Lindahl E., Mousavi M., Zhang X., Ravid R., and Nordberg A. (1999) Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. Brain Res. Mol. Brain Res. 66, 94-103.
24. Holladay M. W., Dart M. J., and Lynch J. K. (1997) Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J. Med. Chem. 40, 4169-4194.
25. Jones G. M., Sahakian B. J., Levy R., Warburton D. M., and Gray J. A. (1992) Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology (Berl.) 108, 485-494.
26. Kellar K. J., Stockmeier C. A., and Martino A. M. (1987) Regulation of β adrenergic and serotonin-S2 receptors in brain by electroconvulsive shock and serotonin. Psychopharmacol. Ser. 3, 99-106.
27. Klimaschewski L., Reuss S., Spessert R., Lobron C., Wevers A., Heym C., Maelicke A., and Schröder H. (1994) Expression of nicotinic acetylcholine receptors in the rat superior cervical ganglion on mRNA and protein level. Brain Res. Mol. Brain Res. 27, 167-173.
28. Levin E. D. (1992) Nicotinic systems and cognitive function. Psychopharmacology (Berl. ) 108, 417-431.
29. Levy M. L., Cummings J. L., and Kahn-Rose R. (1999) Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease. Gerontology 45, 15-22.
30. Lindstrom J., Gullick W., Conti-Tronconi B., and Ellisman M. (1980) Proteolytic nicking of the acetylcholine receptor. Biochemistry 19, 4791-4795.
31. Loo D. T., Copani A., Pike C. J., Whittemore E. R., Walencewicz A. J., and Cotman C. W. (1993) Apoptosis is induced by β-amyloid in cultured central nervous system neurons. Proc. Natl. Acad. Sci. USA 90, 7951-7955.
32. Madhok T. C., Bjercke R. J., Langone J. J., and Sharp B. M. (1992) Brain nicotinic receptors isolated by a monospecific antibody against a synthetic α3 subunit receptor peptide compared to a monoclonal anti-idiotypic (to nicotine) antibody. Biochem. Biophys. Res. Commun. 182, 1303-1308.
33. Marutle A., Warpman U., Bogdanovic N., Lannfelt L., and Nordberg A. (1999) Neuronal nicotinic receptor deficits in Alzheimer patients with the Swedish amyloid precursor protein 670/671 mutation. J. Neurochem. 72, 1161-1169.
34. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E. M. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
35. Meyer E. M., Tay E. T., Papke R. L., Meyers C., Huang G. L., and de Fiebre C. M. (1997) 3-[2,4-Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat α7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner. Brain Res. 768, 49-56.
36. Meyer E. M., Tay E. T., Zoltewicz J. A., Meyers C., King M. A., Papke R. L., and De Fiebre C. M. (1998) Neuroprotective and memory-related actions of novel α7 nicotinic agents with different mixed agonist/antagonist properties. J. Pharmacol. Exp. Ther. 284, 1026-1032.
37. Mirra S. S., Heyman A., McKeel D., Sumi S. M., Grain B. J., Brownlee L. M., Vogel F. S., Hughes J. P., van Belle G., and Berg L. (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41, 479-486.
38. Newhouse P. A., Potter A., and Levin E. D. (1997) Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics. Drugs Aging 11, 206-228.
39. Nordberg A. (1992) Neuroreceptor changes in Alzheimer disease. Cerebrovasc. Brain Metab. Rev. 4, 303-328.
40. Nordberg A. (1994) Human nicotinic receptors - their role in aging and dementia. Neurochem. Int. 25, 93-97.
41. 3]acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci. Lett. 72, 115-119.
42. Nordberg A., Adem A., Hardy J., and Winblad B. (1988) Change in nicotinic receptor subtypes in temporal cortex of Alzheimer brains. Neurosci. Lett. 86, 317-321.
43. Nordberg A., Alafuzoff I., and Winblad B. (1992) Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia. J. Neurosci. Res. 31, 103-111.
44. 11C-nicotine binding in normal and Alzheimer brains - in vivo assessment using positron emission tomography. Alzheimer Dis. Assoc. Disord. 9, 21-27.
45. Peng J. H., Lucero L., Fryer J., Herl J., Leonard S. S., and Lukas R. J. (1999) Inducible, heterologous expression of human α7-nicotinic acetylcholine receptors in a native nicotinic receptor-null human clonal line. Brain Res. 825, 172-179.
46. Peng X., Gerzanixh V., Anand R., Wang F., and Lindstrom J. (1997) Chronic nicotine treatment up-regulates α3 and α7 acetylcholine receptor subtypes expressed by the human neuroblastoma cell line SH-SY5Y. Mol. Pharmacol. 51, 776-784.
47. Perry E. K., Perry R. H., Smith C. J., Purohit D., Bonham J., Dick D. J., Candy J. M., Edwardson J. A., and Fairbairn A. (1986) Cholinergic receptors in cognitive disorders. Can. J. Neurol. Sci. 13, 521-527.
48. Rasband W. S. and Bright D. S. (1995) NIH Image: a public domain image processing program for the Macintosh. Microbeam Anal. Soc. J. 4, 137-149.
49. Reuss S., Schröder B., Schröder H., and Maelicke A. (1992) Nicotinic cholinoceptors in the rat pineal gland as analyzed by western blot, light- and electron microscopy. Brain Res. 573, 114-118.
50. Sahakian B. J. and Coull J. T. (1993) Tetrahydroaminoacridine (THA) in Alzheimer's disease: an assessment of attentional and ninemonic function using CANTAB. Acta Neurol. Scand. Suppl. 149, 29-35.
51. Sargent P. B. (1993) The diversity of neuronal nicotinic acetylcholine receptors. Annu. Rev. Neurosci. 16, 403-443.
52. Schröder H. and Wevers A. (1998) Nicotinic acetylcholine receptors in Alzheimer's disease. Alzheimer's Dis. Rev. 3, 20-27.
53. Smith M. A., Sayre L. M., Monnier V. M., and Perry G. (1996) Oxidative posttranslational modifications in Alzheimer disease. A possible pathogenic role in the formation of senile plaques and neurofibrillary tangles. Mol. Chem. Neuropathol. 28, 41-48.
54. Sugaya K., Giacobini E., and Chiappinelli V. A. (1990) Nicotinic acetylcholine receptor subtypes in human frontal cortex: changes in Alzheimer's disease. J. Neurosci. Res. 27, 349-359.
55. Terzano S., Court J. A., Fornasari D., Griffiths M., Spurden D. P., Lloyd S., Perry R. H., Perry E. K., and Clementi F. (1998) Expression of the α3 nicotinic receptor subunit mRNA in aging and Alzheimer's disease. Brain Res. Mol. Brain Res. 63, 72-78.
56. Viseshakul N., Figl A., Lytle C., and Cohen B. N. (1998) The α4 subunit of rat α4β2 nicotinic receptors is phosphorylated in vivo. Brain Res. Mol. Brain Res. 59, 100-104.
57. Warpman U. and Nordberg A. (1995) Epibatidine and ABT 418 reveal selective losses of α4β2 nicotinic receptors in Alzheimer brains. Neuroreport 6, 2419-2423.
58. Whitehouse P. J., Martino A. M., Antuono P. G., Lowenstein P. R., Coyle J. T., Price D. L., and Kellar K. J. (1986) Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res. 371, 146-151.
59. 3H]nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease: an autoradiographic study. Neurology 38, 720-723.
60. Whiting P., Schoepfer R., Lindstrom J., and Priestley T. (1991) Structural and pharmacological characterization of the major brain nicotinic acetylcholine receptor subtype stably expressed in mouse fibroblasts. Mol. Pharmacol. 40, 463-472.
61. Whiting P. J., Liu R., Morley B. J., and Lindstrom J. M. (1987) Structurally different neuronal nicotinic acetylcholine receptor subtypes purified and characterized using monoclonal antibodies. J. Neurosci. 7, 4005-4016.